Allurion outlines path to FDA submission and expects revenue ramp as B2B2C strategy expands in 2025 Allurion outlines path to FDA submission and expects revenue ramp as B2B2C strategy expands in 2025 Post Contentalur, alur.wsRead More You might also be interested in reading Brady declares $0.24 dividend. May 14, 2025 In Mainstream ← Previous post Next post →